Clinical trial · no report yet · Phase 3
TOP
Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations
- NCT04695925 ↗
- Active not recruiting
- Li Zhang, MD
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Multicentre, Randomized Controlled Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib, Carboplatin and Pemetrexed for Untreated Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations(TOP)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Non-small Cell Carcinoma; EGFR Gene Mutation
- Interventions
- Osimertinib; Pemetrexed; Carboplatin
- Arms
- osimertinib monotherapy · Active comparator
- combination of osimertinib and chemotherapy · Experimental
- Enrollment
- 294
- Primary outcomes
- progression free survival
- Sponsor
- Li Zhang, MD with Cancer Hospital of Guangxi Medical University, First People's Hospital of Foshan, Henan Cancer Hospital
- Start
- Mar 29, 2021
- Primary completion
- Nov 1, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT04695925 · updated Oct 15, 2025
Publications
linked from the registry- Zhou T, Zhou H, Gao F, Feng W, Jiang W, Huang L, Zhao F, Chen L, Ji M, Zhu J, Fang Y, Chen P, Wang P, Wu J, Zhuang L, Liu X, Deng M, Weng G, Li J, Yang C, Zhao H, Yang Y, Zhang L. Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial. JAMA. 2026 Aug 10. doi: 10.1001/jama.2026.10599. Online ahead of print. PubMed 42574006